Watch AURA. Know when insiders buy.
One email the day a filing lands. Free.
AURA
Aura Biosciences, Inc.
6.46
−0.10 −1.52%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $669.9MP/E —DIV YIELD —FCF YIELD -15.43%REV TTM —NET INCOME −$131MNET CASH —52W 4.97 – 8.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$48.1M | −$45.6M | — | -0.48 | −$32.5M | $21K | −$32.5M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$34.9M | −$33.7M | — | -0.50 | −$29.9M | $102K | −$30M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$27.2M | −$25.6M | — | -0.37 | −$20.5M | $176K | −$20.6M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$27.9M | −$26.1M | — | -0.40 | −$20.1M | $45K | −$20.2M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$28.6M | −$27M | — | -0.47 | −$20.8M | $39K | −$20.8M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$29M | −$27.5M | — | -0.55 | −$23.4M | $187K | −$23.5M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$27.8M | −$25.8M | — | -0.52 | −$24M | $299K | −$24.3M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$23.2M | −$21M | — | -0.42 | −$15.3M | $341K | −$15.6M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$22.8M | −$20.3M | — | -0.41 | −$16.1M | $525K | −$16.7M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$22.3M | −$19.7M | — | -0.40 | −$24.5M | $88K | −$24.5M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$24.8M | −$22.1M | — | -0.50 | −$17.4M | $317K | −$17.7M | Mar 24 |
| Q3 2023 · Sep 30 | — | — | — | −$20.5M | −$18.5M | — | -0.48 | −$15.4M | $90K | −$15.5M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$112.8M | −$106.2M | — | -1.76 | −$84.7M | $447K | −$85.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$96.1M | −$86.9M | — | -1.75 | −$79.8M | $1.3M | −$81.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$85M | −$76.4M | — | -1.93 | −$63.8M | $709K | −$64.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$60.3M | −$58.8M | — | -1.96 | −$54.6M | $1.1M | −$55.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$35.3M | −$35.3M | — | -8.95 | −$32.4M | $2.1M | −$34.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$22.2M | −$22.2M | — | -82.06 | −$24.3M | $771K | −$25.1M | — | — |
Every number comes from Aura Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.